Pulmokine, Inc.

Company Information
Address 7 University Place, Rm B127
Rensselaer, NY, 12144-3463

http://www.pulmokine.net

Information

DUNS: 808479906

# of Employees: 4


Ownership Information

HUBZone Owned: N

Socially and Economically Disadvantaged: N

Woman Owned: N



Award Charts




Award Listing

  1. A phosphopeptide multiplex PRM mass spectroscopic biomarker assay for PAH

    Amount: $515,573.00

    The purpose of this phase SBIR grant is to develop a quantitative phosphopeptide biomarker assay for pulmonary arterial hypertension PAH The commercial product will consist of a kit of stable iso ...

    SBIRPhase I2017Department of Health and Human Services National Institutes of Health
  2. A novel inhaled c-kit/PDGFR inhibitor for the treatment of asthma

    Amount: $337,324.00

    DESCRIPTION provided by applicant The purpose of this project is to develop an inhaled combined c kit PDGFR inhibitor as a treatment for asthma Asthma is a chronic inflammatory disease characteri ...

    SBIRPhase I2016Department of Health and Human Services
  3. An inhaled PDGF receptor inhibitor for the treatment of pulmonary arterial hypertension

    Amount: $3,004,131.00

    DESCRIPTION provided by applicant Pulmokine is developing a novel inhaled PDGF receptor PDGFR kinase inhibitor PK as a treatment for Pulmonary Arterial Hypertension PAH The purpose of th ...

    SBIRPhase II2015Department of Health and Human Services National Institutes of Health
  4. IGF::OT::IGF Aerosolized Delivery of Anti-Tubercular Drugs

    Amount: $224,960.00

    Develop an inexpensive, easy to use, aerosolized delivery system of a combination of anti-tubercular drugs that could be used for the treatment of multi-drug resistant tuberculosis (MDR TB ). PUBLIC H ...

    SBIRPhase I2013Department of Health and Human Services
  5. An inhaled PDGF receptor inhibitor for the treatment of pulmonary arterial hyper

    Amount: $2,267,504.00

    DESCRIPTION (provided by applicant): The purpose of this Phase II project is to develop a new treatment for pulmonary arterial hypertension (PAH) consisting of the inhaled platelet derived growth fact ...

    SBIRPhase II2012Department of Health and Human Services
  6. A novel JAK inhibitor for the treatment of pulmonary arterial hypertension

    Amount: $311,629.00

    DESCRIPTION (provided by applicant): Pulmonary arterial hypertension (PAH) is a rare disease associated with high morbidity and mortality. The purpose of this proposal is to develop a novel combined J ...

    SBIRPhase I2010Department of Health and Human Services
  7. A PDGFR inhibitor for the treatment of pulmonary arterial hypertension

    Amount: $351,008.00

    DESCRIPTION (provided by applicant): Pulmonary arterial hypertension (PAH) is a devastating disease associated with high morbidity and mortality. The purpose of this proposal is to develop a novel hig ...

    SBIRPhase I2010Department of Health and Human Services

Agency Micro-sites

SBA logo
Department of Agriculture logo
Department of Commerce logo
Department of Defense logo
Department of Education logo
Department of Energy logo
Department of Health and Human Services logo
Department of Homeland Security logo
Department of Transportation logo
Environmental Protection Agency logo
National Aeronautics and Space Administration logo
National Science Foundation logo
US Flag An Official Website of the United States Government